Philadelphia chromosome‐positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Hematology"
DOI: 10.1002/ajh.25648
Abstract: Despite the advances in the management of Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukemia (ALL) with the introduction of tyrosine kinase inhibitors (TKIs), relapses remain challenging. We reviewed clinical data from adult patients with Ph + ALL who… read more here.
Keywords: first relapse; positive acute; lymphoblastic leukemia; acute lymphoblastic ... See more keywords
Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer"
DOI: 10.1002/cncr.31082
Abstract: Health‐related quality of life (HRQOL) in patients with chronic‐phase chronic myeloid leukemia (CML) is important because of the requirement for long‐term treatment. This study assessed HRQOL in bosutinib‐treated patients with Philadelphia chromosome–positive CML and resistance… read more here.
Keywords: long term; myeloid leukemia; chronic myeloid; chromosome positive ... See more keywords
Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors
Sign Up to like & getrecommendations! Published in 2021 at "Cancer"
DOI: 10.1002/cncr.33529
Abstract: The achievement of a 3‐month complete molecular response (CMR) is a major prognostic factor for survival in patients with Philadelphia chromosome (Ph)‐positive acute lymphoblastic leukemia (ALL). However, 25% of patients relapse during therapy with tyrosine… read more here.
Keywords: molecular response; positive acute; patients philadelphia; complete molecular ... See more keywords
Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Current Treatment Options in Oncology"
DOI: 10.1007/s11864-019-0603-z
Abstract: With the introduction of tyrosine kinase inhibitors (TKIs) in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the prognosis of patients has improved dramatically. Currently, the standard of care in the frontline setting… read more here.
Keywords: positive acute; treatment; lymphoblastic leukemia; chromosome positive ... See more keywords
New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Current Hematologic Malignancy Reports"
DOI: 10.1007/s11899-017-0372-3
Abstract: Purpose of ReviewTo review recent studies that address important questions regarding the treatment of Philadelphia chromosome-positive ALL.Recent FindingsLess intensive non-myelosuppressive induction approaches can produce comparable anti-leukemic responses with less toxicity. Second-generation tyrosine kinase inhibitors (TKIs)… read more here.
Keywords: new treatment; treatment strategies; chromosome positive; philadelphia chromosome ... See more keywords
Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of adolescent and young adult oncology"
DOI: 10.1089/jayao.2021.0200
Abstract: Philadelphia chromosome positive (Ph+) B cell acute lymphoblastic leukemia (ALL) is extremely rare in pregnancy. Although the use of tyrosine kinase inhibitors (TKIs) has significantly improved outcomes of patients with Ph+ ALL, its use during… read more here.
Keywords: chromosome positive; philadelphia chromosome; lymphoblastic leukemia; pregnancy ... See more keywords
Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study
Sign Up to like & getrecommendations! Published in 2022 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000001455
Abstract: Although Philadelphia chromosome-positive acute leukemia (Ph+-ALL) has been revolutionized with tyrosine kinase inhibitors (TKIs), resistance and mutation are universal events during treatment with first-generation and second-generation TKIs. The present third-generation TKI has a dose-dependent, increased… read more here.
Keywords: newly diagnosed; generation; chromosome positive; philadelphia chromosome ... See more keywords
TKIs combined with chemotherapy followed by allo-HSCT in Philadelphia chromosome-positive myelodysplastic syndrome: A case report and literature review
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031874
Abstract: Introduction: Philadelphia chromosome (Ph) positive myelodysplastic syndrome (MDS) is a very rare disease. At present, the specific role of Ph in MDS is not clear, but such patients seem to have a poor prognosis, so… read more here.
Keywords: mds; chemotherapy followed; chromosome positive; philadelphia chromosome ... See more keywords
Droplet digital polymerase chain reaction improves the detection of BCR-ABL1 kinase domain mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sign Up to like & getrecommendations! Published in 2023 at "International journal of laboratory hematology"
DOI: 10.1111/ijlh.14069
Abstract: INTRODUCTION Sanger sequencing (SS) is the most frequently used method for detecting ABL1 kinase domain (KD) mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). However, it cannot detect low levels of mutation.… read more here.
Keywords: kinase domain; chromosome positive; abl1 kinase; philadelphia chromosome ... See more keywords
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias
Sign Up to like & getrecommendations! Published in 2020 at "Acta Haematologica"
DOI: 10.1159/000506346
Abstract: Background: Philadelphia chromosome-positive (Ph+) advanced leukemias, including acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) in myeloid blast phase (MBP), have poor outcomes. Venetoclax has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in… read more here.
Keywords: positive advanced; chromosome positive; philadelphia chromosome; myeloid ... See more keywords
Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Translational Medicine"
DOI: 10.1186/s12967-017-1286-5
Abstract: BackgroundAs one of the major treatment obstacles in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), relapse of Ph+ALL may result from the persistence of leukemia-propagating cells (LPCs). Research using a xenograft mouse assay recently determined that… read more here.
Keywords: propagating cells; ruxolitinib nilotinib; chromosome positive; philadelphia chromosome ... See more keywords